Medicine & Science
Making a Difference for
Our focus is on providing new solutions to solve today’s problems in fighting cancer with targeted molecular therapies.
Working on Now
We are committed to discovering, developing, and commercializing targeted molecular therapies to benefit cancer patients.
A Healthier Tomorrow
for Cancer Patients
We are dedicated to improving patients’ lives by increasing the treatment potential of currently marketed & developmental cancer drugs.
Genprex is a clinical-stage biopharmaceutical company developing targeted molecular therapies for cancer.
We are developing molecular therapies that control universal cancer pathways to unlock the unrealized potential of targeted cancer therapies, such as tyrosine kinase inhibitory drugs (TKIs).
Our tumor suppression technologies are pan-kinase inhibitors that work to induce apoptosis (programmed cell death) in cancer cells and to control cell signaling and inflammatory pathways to treat cancer at the molecular level. Our discoveries and R&D programs have been the subject of more than 30 peer-reviewed publications and have been supported by corporate investment and grants from the NIH, SBIR, U.S. Department of Treasury, and State of Texas. We control a portfolio of 30 issued and 6 pending patents covering tumor suppressors, therapeutics, diagnostics, nanovesicle delivery systems, and manufacturing processes.
Oncoprex™, our lead product candidate, regulates the activation of multiple oncogenic kinases and has shown synergistic anti-cancer activity when combined with a number of kinase inhibitor drugs (KIs). Oncoprex is expected to participate in major oncology markets in combination with KIs.
Rodney Varner, J.D.
Executive Chairman & CEO
Julien Pham, M.D., M.P.H.
Chief Operating Officer
Ryan Confer, M.S.
Chief Financial Officer
Elizabeth Han, J.D.
David E. Friedman
Robert E. Pearson
Jack A. Roth, M.D.
Key Medical & Scientific Advisor, SAB Chairman
James E. Rothman, Ph.D.
Strategic Advisor to the Board of Directors